Several new research projects have been approved for funding by trustees:

Testing dual and triple glucagon family receptor agonists as Parkinson’s disease therapeutics - a project led by Dr Konrad Talbot at The Cedars -Sinai Medical Centre, Los Angeles.

Preclinical evaluation of D-PUFAs as a therapeutic intervention for PD - Two linked projects one led by Professor Patrik Brundin at The Van Andel Research Institute, Grand Rapids, USA and the other led by Professor Flint Beal of Weill Cornell Medical College, New York. 

To provide information on how much Ambroxol (a commonly available anti-mucolytic drug) crosses the blood brain barrier and whether it engages with a targeted enzyme - a project led by Professor Tony Schapira of The Royal Free Hospital